Intravitreal Ranibizumab (Lucentis) for the Treatment of Diabetic Macular Edema: A Systematic Review and Meta-Analysis of Randomized Clinical Control Trials

References

• Paulus YM, Gariano RF. Diabetic retinopathy: A growing concern in an aging population. Geriatrics 2009;64:16–20.
   PubMed Web of Science ®Google Scholar
• Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther 2008;88:1254–1264.
   PubMed Web of Science ®Google Scholar
• Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology 1994;101:1061–1070.
   PubMed Web of Science ®Google Scholar
• Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: The twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009;116:497–503.
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91:1464–1474.
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796–1806.
   PubMed Web of Science ®Google Scholar
• Farahvash MS, Mahmoudi AH, Farahvash MM et al. The impact of macular laser photocoagulation on contrast sensitivity function in patients with clinically significant macular edema. Arch Iran Med 2008;11:143–147.
   PubMed Web of Science ®Google Scholar
• Aiello LP, Bursell SE, Clermont A et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997;46:1473–1480.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Tatlipinar S, Shah SM et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006;142:961–969.
   PubMed Web of Science ®Google Scholar
• Cunningham ET Jr., Adamis AP, Altaweel M et al.; Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112:1747–1757.
   PubMed Web of Science ®Google Scholar
• Ozturk BT, Kerimoglu H, Adam M, Gunduz K, Okudan S. Glucose regulation influences treatment outcome in ranibizumab treatment for diabetic macular edema. J Diabetes Complicat 2011;25:298–302.
   PubMed Web of Science ®Google Scholar
• Faghihi H, Roohipoor R, Mohammadi SF et al. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 2008;18:941–948.
   PubMed Web of Science ®Google Scholar
• Goyal S, Lavalley M, Subramanian ML. Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2011;249:15–27.
   PubMed Web of Science ®Google Scholar
• Ozturk BT, Kerimoglu H, Bozkurt B, Okudan S. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema. J Ocul Pharmacol Ther 2011;27:373–377.
   PubMed Web of Science ®Google Scholar
• Massin P, Bandello F, Garweg JG et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:2399–2405.
   PubMed Web of Science ®Google Scholar
• Mitchell P, Bandello F, Schmidt-Erfurth U et al.; RESTORE study group. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615–625.
   PubMed Web of Science ®Google Scholar
• Elman MJ, Aiello LP, Beck RW et al.; Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064–1077.e35.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Khwaja AA et al.; READ-2 Study Group. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010;117:2146–2151.
   PubMed Web of Science ®Google Scholar
• Elman MJ, Bressler NM, Qin H et al.; Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118:609–614.
   PubMed Web of Science ®Google Scholar
• Sun JK. Intravitreal anti-VEGF therapy with prompt or deferred laser compared with steroid with prompt laser and prompt laser alone for treatment of diabetic macular edema. Curr Diab Rep 2011;11:227–229.
   PubMedGoogle Scholar
• Nguyen QD, Shah SM, Heier JS et al.; READ-2 Study Group. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2009;116:2175–81.e1.
   PubMed Web of Science ®Google Scholar
• Googe J, Brucker AJ, Bressler NM et al.; Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina (Philadelphia, Pa) 2011;31:1009–1027.
   PubMed Web of Science ®Google Scholar
• Malgorzata F, Stankiewicz A. Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes. Med Sci Monit 2011;17:CR485–CR490.
   PubMed Web of Science ®Google Scholar
• Ahmadieh H, Ramezani A, Shoeibi N et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008;246:483–489.
   PubMed Web of Science ®Google Scholar
• Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114:1179–1185.
   PubMed Web of Science ®Google Scholar
• Tonello M, Costa RA, Almeida FP, Barbosa JC, Scott IU, Jorge R. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 2008;86:385–389.
   PubMed Web of Science ®Google Scholar
• Kaiser PK. Ranibizumab: The evidence of its therapeutic value in neovascular age-related macular degeneration. Core Evid 2008;2:273–294.
   PubMedGoogle Scholar
• Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726–733.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS et al.; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–1431.
   PubMed Web of Science ®Google Scholar
• Heier JS, Boyer DS, Ciulla TA et al.; FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: Year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124:1532–1542.
   PubMed Web of Science ®Google Scholar
• Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116:57–65.e5.
   PubMed Web of Science ®Google Scholar
• Kang SW, Sa HS, Cho HY, Kim JI. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol 2006;124:653–658.
   PubMed Web of Science ®Google Scholar